Nov 10
MEDS · DataMeds AI, Inc.
$0.87
-0.08 (-8.70%)
At close · Nov 12
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 17, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within twelve months from the date these unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 17, 2026
Market Cap
$2.66M
Shares
3.06M
Volume · Nov 12
155.41K
Avg daily vol (3M)
6.43M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.87
Open$0.94
Day$0.87–1.00
52W close$0.85–32.30
Avg vol 30d1.7M
Short int371K · 12.1% of shares · 1.0d
Short vol40%
DataFeb 2025–Nov 2026
Filing10-Q · Aug 17
Latest documents
2026
Nov 5
Current report
8-K
Events of Nov 3
Letter of Intent Terminated Without Share Issuance
DataMEDS terminated its October 19, 2026 letter of intent effective November 3, 2026, citing market conditions; no shares will be issued and no fees or obligations are owed. Separate REBOOT and PharmacyChain agreements remain in force.
Oct 26
Current report
8-K
Events of Oct 21
Entered into a material agreement, Regulation FD disclosure
DataMeds AI entered a non-binding LOI to acquire QLPM and Health Lives Here assets and licenses, targeting a fourth quarter 2026 close, with REBOOT, EOS and Scilex receiving royalties of 6%, 5% and 5%.
Oct 20
Current report
8-K
Events of Oct 19
Regulation FD disclosure, Other events
DataMeds AI, Inc. regained compliance with Nasdaq Listing Rule 5550(b)(1) after stockholders’ equity exceeded $2,500,000; Nasdaq confirmed compliance on October 19, 2026, but warned delisting may follow if compliance is not evidenced in the next periodic report.
Oct 16
Current report
8-K
Events of Oct 13
Entered into a material agreement, Delisting notice or listing transfer, Unregistered sale of equity
DataMeds AI entered an IP license deal with REBOOT Health AI, issuing 666,667 shares valued at $2,000,000 plus a $50,000 payment. The Company now believes its stockholders' equity exceeds the $2,500,000 Nasdaq minimum and awaits Nasdaq confirmation.
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$8.02M
Trailing 12 months
Net income (TTM)
−$88.28M
Trailing 12 months
Revenue growth YoY
-77.2%
Year over year
Operating margin
-875.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$29.35M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+108.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
12.1%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.72
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−83%
below
Price vs 50-day avg
−65%
below
RSI (14)
28
oversold
MACD trend
Negative
52-week position
0%
near low
Momentum
relative strength
1-month return
−69%
trailing
6-month return
−79%
trailing
YTD return
−96%
this year
Relative strength
−81%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
11 of 9 funds reported for Sep 30 · net +18.7K sh shares · +5 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.13% of shares out · ▼ -22.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — mid 1-yr range
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
+29%
Y/Y
Gross margin
-28%
contracting
EPS growth
−853%
Y/Y
Balance sheet
$23.4M
net debt
Quant / Vol
risk profile
Volatility
339%
annualized · 1-yr
Max drawdown
−97%
past year
ATR
39.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the 8-K filed May 19, 2026
Revenue
· Q2-2026
$1.78M
Guided vs delivered
· last 1 settled
Revenue
Q2-2026
guided $1.78M
$1.78M
Beat +0.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−83%
Bearish
Price vs 50-day avg
−65%
Bearish
RSI (14)
28
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
11 of 9 funds reported for Sep 30 · net +18.7K sh shares · +5 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.13% of shares out · ▼ -22.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $32
vs 200-day avg -83%
vs 50-day avg -65%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MEDS
this stock
DataMeds AI, Inc.
|
$2.66M | — | +28.7% | — | 12.1% |
|
MCK
Mckesson Corp
|
$124.35B | +31.3% | +3.1% | 27.8 | 1.7% |
|
COR
Cencora, Inc.
|
$66.67B | +3.4% | +9.3% | 25.9 | 1.7% |
|
CAH
Cardinal Health Inc
|
$64.29B | +35.3% | +14.2% | — | 3.3% |
|
HSIC
Henry Schein Inc
|
$9.52B | +14.0% | +5.9% | 23.6 | 8.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MEDS | -28.7% | -69.5% | -79.0% | -54.7% | -95.7% |
| SPY | +3.3% | -1.9% | +1.5% | +0.2% | +11.0% |
| vs SPY | -32.0% | -67.6% | -80.6% | -54.9% | -106.7% |